If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2002, Ph.D. National Taiwan University
  • 1994, M.S. Taipei Medical University

Experience

  • 2019- Director, Ph.D Program in Biotechnology Research and Development
  • 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery
  • 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery
  • 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery
  • 2008-2013 Assistant Professor, Department of Pharmacology
  • 2009-2013 Assistant Investigator, National Health Research Institutes
  • 2007-2009 Assistant Investigator, National Taiwan University
  • 2002-2007 Postdoctor, National Taiwan Universiy
  • 1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

  • Drug Discovery
  • Disease animal model
  • Pharmacology

URL

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
Apoptosis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Histone Deacetylase Inhibitors Medicine & Life Sciences
Smooth Muscle Myocytes Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Indazoles Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2019

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)

Pan, S.

8/1/187/31/19

Project: b - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究

Pan, S.

12/1/1710/31/18

Project: b - Ministry of Science and Technology

選擇性HDAC1及2抑制劑作為新穎性抗癌藥物之藥物開發與藥理機轉探討

Pan, S.

8/1/177/31/18

Project: b - Ministry of Science and Technology

新穎性pan-HDAC 抑制劑抑制血管新生之藥物研發與藥理作用機轉(3/3)

Pan, S.

8/1/167/31/17

Project: b - Ministry of Science and Technology

Research Output 1996 2018

  • 2745 Citations
  • 30 h-Index
  • 121 Article
2 Citations

1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC

Ojha, R., Huang, H. L., HuangFu, W. C., Wu, Y. W., Nepali, K., Lai, M. J., Su, C. J., Sung, T. Y., Chen, Y. L., Pan, S. L. & Liou, J. P., Apr 25 2018, In : European Journal of Medicinal Chemistry. 150, p. 667-677 11 p.

Research output: Contribution to journalArticle

Hydroxamic Acids
Histone Deacetylase Inhibitors
Antineoplastic Agents
Protein Isoforms
Cells

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy

Lin, S. Y., Yeh, T. K., Song, J. S., Hung, M. S., Cheng, M. F., Liao, F. Y., Li, A. S., Cheng, S. Y., Lin, L. M., Chiu, C. H., Wu, M. H., Lin, Y. J., Hsiao, W., Sun, M., Wang, Y. H., Huang, C. H., Tang, Y. C., Chang, H. H., Huang, Z. T., Chao, Y. S. & 5 othersShih, C., Pan, S. L., Wu, S. Y., Kuo, C. C. & Ueng, S. H., Apr 1 2018, In : Bioorganic Chemistry. 77, p. 600-607 8 p.

Research output: Contribution to journalArticle

Indoleamine-Pyrrole 2,3,-Dioxygenase
Tumors
Neoplasms
T-cells
Pharmaceutical Preparations
1 Citations

A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo

Wu, Y. W., Hsu, K. C., Lee, H. Y., Huang, T. C., Lin, T. E., Chen, Y. L., Sung, T. Y., Liou, J. P., Hwang-Verslues, W. W., Pan, S. L. & HuangFu, W. C., Mar 13 2018, In : Frontiers in Pharmacology. 9, MAR, 205.

Research output: Contribution to journalArticle

Tubulin Modulators
Histone Deacetylases
Neoplasms
Tubulin
Molecular Docking Simulation

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells

Tu, H. J., Lin, Y. J., Chao, M. W., Sung, T. Y., Wu, Y. W., Chen, Y. Y., Lin, M. H., Liou, J. P., Pan, S. L. & Yang, C. R., Dec 29 2018, In : Clinical Epigenetics. 10, 1, 162.

Research output: Contribution to journalArticle

Leukemia
Vincristine
Doxorubicin
Drug Therapy
Neoplasms
2 Citations

1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma

Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., Nov 10 2017, In : European Journal of Medicinal Chemistry. 140, p. 84-91 8 p.

Research output: Contribution to journalArticle

Ubiquitin-Protein Ligases
Multiple Myeloma
Tumors
Lead compounds
Growth